Overview

* Plus Therapeutics ( PSTV ) Q3 net loss widens to $4.4 mln from $2.9 mln last year

* Company received $1.9 mln advance from CPRIT for radiotherapeutic development

* Announced national coverage agreement with UnitedHealthcare for CNSide diagnostics

Outlook

* Plus Therapeutics ( PSTV ) plans to expand commercial team and footprint for CNSide in Q4

* Company aims to clarify REYOBIQ clinical development plan with FDA

* Plus Therapeutics ( PSTV ) to bolster financial position in capital markets

Result Drivers

* CNSIDE EXPANSION - Plus Therapeutics ( PSTV ) expanded commercial readiness for CNSide diagnostics, securing national coverage with UnitedHealthcare

* CPRIT GRANT - Received $1.9 mln advance payment from CPRIT for leptomeningeal cancer targeted radiotherapeutic development

* REYOBIQ TRIAL RESULTS - Presented positive ReSPECT-LM Phase 1 trial results showing promising efficacy for leptomeningeal metastases

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$4.42

Income mln

Q3 $5.87

Operatin mln

g

Expenses

Q3 -$4.48

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Plus Therapeutics Inc ( PSTV ) is $4.00, about 86.5% above its October 29 closing price of $0.54

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)